Project Manager Professional & Customer Services (m/f/d)

Project Manager Professional & Customer Services (m/f/d)

We are seeking for our headquarters in Heidelberg a highly motivated

Project Manager Professional & Customer Services (m/f/d)

As a member of the Project Management team, you will be responsible for the coordination and steering of customer onboarding and professional service activities in the context of Molecular Health’s MH Guide product suite. Furthermore, together with a team of customer support, product management, software development, and data management specialists, you will be part of the customer engagement team. 

Your tasks in detail

  • Steering of projects professional service projects
  • Customer requirement management, specification and proposal writing, coordination of customer-specific implementation activities and alignment with the overall product release cycle. Among others those are:
    –  Customer report and report interface adaptations
    –  NGS based input data adaptation/preprocessing e.g. fastq filtering or VCF adaptations to MH’s standard format
    –  Customer knowledge base data import
  • Supporting Sales and Scientific Field Support in proposal generation and in customer meetings
  • Participate in 2nd level support of our customers 

Your skills and qualifications

  • University degree, ideally with a doctorate in biomedical sciences
  • Expertise in next-generation sequencing methods and technology
  • Ideally bioinformatic and data analytical skills
  • Good knowledge and experience in project management
  • Organizational skills and flexibility
  • Teamwork
  • Independent and structured work and a quick learning
  • Strong communication, networking, and presentation skills
  • Excellent knowledge of English
  • Versed in dealing with all MS Office products incl. Project planning tools such as MS Project

We offer

  • An innovative, exciting international company that values employees who can think outside of the box, who want to make a difference and strike out in a new direction
  • A challenging, stimulating scientific and professional environment with a focus on innovation and on the continuous development of our company
  • A modern working environment in a new office building
  • A multicultural team and attractive company events, together with an open culture of trust
  • Excellent location in the center of Heidelberg
  • Home office opportunities
  • Opportunities for personal development in a global company
  • Competitive compensation and attractive benefits package, flexible working models


Take the first step and contact us!

We are looking forward to receiving your complete application (cover letter, CV and certificates), in English or German, including your salary expectations and earliest start date.

Please send it via email to Thorsten Vogt

 

 
For further information on how your data will
be processed in the context of an application, please follow the link:
www.molecularhealth.com/en/privacy/


Molecular Health believes in the principles of equal opportunities, diversity and workplace integration

DOWNLOAD
PDF Download

Senior Bioinformatics Scientist (m/f/d)

Senior Bioinformatics Scientist (m/f/d)

We are seeking for our headquarters in Heidelberg a highly motivated

Senior Bioinformatics Scientist (m/f/d)

As a member of the Biomedical Data Connection team in the Research department, you will be prototyping innovative tools and processes to support a revolutionary, data-driven technology that enables precision medicine. 

Your tasks include evaluation of new data resources and computational tools, as well as exploring ways to integrate them with the existing data world. You will conceptualize, develop, and maintain processes to harmonize and connect data, as well as web interfaces to present them in a comprehensive way. Support for services and bespoke solutions for customers, e.g. from the pharmaceutical industry, will be among the responsibilities. Most of this will be done in collaboration with other teams such as biomedical curators, ETL, and software development.

Your skills and qualifications

  • PhD in computational biology, bioinformatics, or a closely related field
  • Broad hands-on experience in bioinformatics programming, including shell scripting, object-oriented program-ming (either Perl or Python) and experience with RDBMS systems (e.g. PostgreSQL, MySQL, etc.)
  • Comprehensive experience with data sources for molecular pathways, protein structures, and molecular interactions
  • Several years of experience in at least three of the following areas:
    – Profound knowledge of standard bioinformatics algorithms and databases, including protein and nucleotide sequence analysis
    – Genome annotation software (e.g. the EnsEMBL Perl API)
    – Application and practical understanding of standard machine learning methods like SVM, artificial neural networks etc.
    – A strong grasp of molecular cancer biology and genetics
    – Wet lab experience in molecular/cellular biology/next-generation sequencing
  • Strong analytical and problem-solving skills and scientific creativity are essential
  • Clear sense of organization, purpose, and accountability
  • Ability to work on multiple projects in parallel
  • Able to work independently, dependable, focused, project- and team-oriented
  • Excellent oral and written communication skills
  • Work experience in industry is considered a strong plus
  • Fluent in English (spoken and written)

We offer

  • An innovative, exciting international company that values employees who can think outside of the box, who want to make a difference and strike out in a new direction
  • A challenging, stimulating scientific and professional environment with a focus on innovation and on the continuous development of our company
  • A modern working environment in a new office building
  • A multicultural team and attractive company events, together with an open culture of trust
  • Excellent location in the center of Heidelberg
  • Home office opportunities
  • Opportunities for personal development in a global company
  • Competitive compensation and attractive benefits package, flexible working models


Take the first step and contact us!

We are looking forward to receiving your complete application (cover letter, CV and certificates), in English or German, including your salary expectations and earliest start date.

Please send it via email to Thorsten Vogt

 

 
For further information on how your data will
be processed in the context of an application, please follow the link:
www.molecularhealth.com/en/privacy/


Molecular Health believes in the principles of equal opportunities, diversity and workplace integration

DOWNLOAD
PDF Download

Head of Marketing & PR (m/f/d)

Head of Marketing & PR (m/f/d)

We are seeking for our headquarters in Heidelberg a highly motivated

Head of Marketing & PR (m/f/d)

In this role you will report to the SVP, Head of the Business Unit Clinical Decision Support and handle Corporate Marketing as well as global Product Marketing. You plan, develop and implement market strategies and market activities. You work creatively, sales-oriented, globally and based on the overall corporate strategy.

In this respect the following responsibilities and activities are part of job description

  • Lead the Marketing Team with actual 3 employees
  • Hand-on operational project work
  • Responsibility for the strategic and content-related positioning and direction of our marketing activities
  • Actively promote company news and (product related) achievements including article development, formal press release distribution, and other media-related activities.
  • Market and competitor monitoring
  • Conception and Implementation of global marketing strategies for the respective countries
  • Developing suitable marketing concepts for new and existing products with the team
  • Cooperation with Molecular Health Management, Product Management and Business Units, as well as Quality Management
  • Online and digital marketing: strategy development and collaboration in the creation of content (editorial plan) for social media and other digital channels (newsletter, website), initiation or maintenance of SEO and SEM
  • Budget planning and monitoring
  • Briefing and coordination of external agencies

Your skills and qualifications

The ideal candidate is an experienced Marketing Manager with a proven track record preferred in Biotechnology, Pharma or Diagnostic.

  • Successfully completed business studies, with a focus on marketing, natural sciences, or medicine.
  • At least 5 years of professional experience in B2B marketing (ideally in the healthcare, pharmaceutical or life science industry)
  • Marketing professional with hands-on experience in all areas of online and offline marketing
  • Proven track record of successfully implemented marketing programs
  • Creativity, outgoing nature, and ability to build and maintain networks
  • Experience in managing employees
  • Very good written and spoken German and English skills
  • Good knowledge of MS-Office, experience with CMS tools (WordPress) and online marketing tools (e.g. MailChimp, Google Analytics, Google Ads, Facebook Ads, LinkedIn Advertising)

We offer

  • An innovative, exciting international company that values employees who can think outside of the box, who want to make a difference and strike out in a new direction
  • A challenging, stimulating scientific and professional environment with a focus on innovation and on the continuous development of our company
  • A modern working environment in a new office building
  • A multicultural team and attractive company events, together with an open culture of trust
  • Excellent location in the center of Heidelberg
  • Home office opportunities
  • Opportunities for personal development in a global company
  • Competitive compensation and attractive benefits package, flexible working models


Take the first step and contact us!

We are looking forward to receiving your complete application (cover letter, CV and certificates), in English or German, including your salary expectations and earliest start date.

Please send it via email to Thorsten Vogt

 

 
For further information on how your data will
be processed in the context of an application, please follow the link:
www.molecularhealth.com/en/privacy/


Molecular Health believes in the principles of equal opportunities, diversity and workplace integration

DOWNLOAD
PDF Download

The potential of liquid biopsies for early cancer detection powered by ONCOCATCH and MH Guide

The potential of liquid biopsies for early cancer detection powered by ONCOCATCH and MH Guide

Molecular Health will join partner EONE-Diagnomics Genome Center (EDGC) in the EDGC seminar “Liquid biopsy for early detection of multiple cancers and Molecular Health GmbH introduction” on Wednesday, 13 October at 16:00–17:00 Korean Standard Time (GMT+9).

An international joint venture between EONE Laboratories and Diagnomics, EDGC develops novel genome analysis technologies to advance diagnostic capabilities in a broad range of diseases and over the lifetime of a patient. Their advanced tools in precision and personalized medicine include ONCOCATCH, an IVD service for cancer detection based on the analysis of circulating tumor DNA in liquid biopsies.

MH Guide from Molecular Health is an EU-registered IVD software that supports treatment decisions via expert annotation and interpretation of genomic data, including the analysis of liquid biopsies. By evaluating genomic data in the context of a comprehensive biomedical information landscape, MH Guide delivers up-to-date and easy-to-use information on clinically relevant biomarkers and clinical trials.

The joint seminar will discuss the unique advantages of coupling ONCOCATCH and MH Guide to evaluate cancer variants in blood for timely, evidence-based treatment decisions. Please join us for this informative presentation.

https://forms.gle/Yh79n1tYJHmkWRXn8

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide

Publications

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide

BRCA1/2 variants are prognostic biomarkers for hereditary breast and/or ovarian cancer (HBOC) syndrome and predictive biomarkers for PARP inhibition. In this study, we benchmarked the classification of BRCA1/2 variants from patients with HBOC-related cancer using MH BRCA, a novel computational technology that combines the ACMG guidelines with expert-curated variant annotations.

 

Evaluation of BRCA1/2 variants (n = 1040) taken from four HBOC studies showed strong concordance within the pathogenic (98.1%) subset. Comparison of MH BRCA’s ACMG classification to ClinVar submitter content from ENIGMA, the international consortium of investigators on the clinical significance of BRCA1/2 variants, the ARUP laboratories, a clinical testing lab of the University of UTAH, and the German Cancer Consortium showed 99.98% concordance (4975 out of 4976 variants) in the pathogenic subset. In our patient cohort, refinement of patients with variants of unknown significance reduced the uncertainty of cancer-predisposing syndromes by 64.7% and identified three cases with potential family risk to HBOC due to a likely pathogenic variant BRCA1 p.V1653L (NM_007294.3:c.4957G > T; rs80357261). To assess whether classification results predict PARP inhibitor efficacy, contextualization with functional impact information on DNA repair activity were performed, using MH Guide. We found a strong correlation between treatment efficacy association and MH BRCA classifications. Importantly, low efficacy to PARP inhibition was predicted in 3.95% of pathogenic variants from four examined HBOC studies and our patient cohort, indicating the clinical relevance of the consolidated variant interpretation.

 

View full text: https://www.mdpi.com/1422-0067/21/11/3895/htm.

Adverse Event Circumstances and the Case of Drug Interactions.

Publications

Adverse Event Circumstances and the Case of Drug Interactions.

Adverse events are a common and for the most part unavoidable consequence of therapeutic intervention. Nevertheless, available tomes of such data now provide us with an invaluable opportunity to study the relationship between human phenotype and drug-induced protein perturbations within a patient system. Deciphering the molecular basis of such adverse responses is not only paramount to the development of safer drugs but also presents a unique opportunity to dissect disease systems in search of novel response biomarkers, drug targets, and efficacious combination therapies. Inspired by the potential applications of this approach, we first examined adverse event circumstances reported in FAERS and then performed a molecular level interrogation of cancer patient adverse events to investigate the prevalence of drug-drug interactions in the context of patient responses. We discuss avoidable and/or preventable cases and how molecular analytics can help optimize therapeutic use of co-medications. While up to one out of three adverse events in this dataset might be explicable by iatrogenic, patient, and product/device related factors, almost half of the patients in FAERS received multiple drugs and one in four may have experienced effects attributable to drug interactions.

 

Healthcare Basel. 2019 Mar 19;7(1); Soldatos, Jackson. doi: 10.3390/healthcare7010045.

In Silico Profiling of Clinical Phenotypes for Human Targets Using Adverse Event Data.

Publications

In Silico Profiling of Clinical Phenotypes for Human Targets Using Adverse Event Data.

We present a novel approach for the molecular transformation and analysis of patient clinical phenotypes. Building on the fact that drugs perturb the function of targets/genes, we integrated data from 8.2 million clinical reports detailing drug-induced side effects with the molecular world of drug-target information. Using this dataset, we extracted 1.8 million associations of clinical phenotypes to 770 human drug-targets. This collection is perhaps the largest phenotypic profiling reference of human targets to-date, and unique in that it enables rapid development of testable molecular hypotheses directly from human-specific information. We also present validation results demonstrating analytical utilities of the approach, including drug safety prediction, and the design of novel combination therapies. Challenging the long-standing notion that molecular perturbation studies cannot be performed in humans, our data allows researchers to capitalize on the vast tomes of clinical information available throughout the healthcare system.


Soldatos, Taglang, Jackson; High Throughput. 2018 Nov 23;7(4). doi: 10.3390/ht7040037.

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data.

Publications

Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data.

Recent studies suggest that combining nivolumab with ipilimumab is a more effective treatment for melanoma patients, compared to using ipilimumab or nivolumab alone. However, treatment with these immunotherapeutic agents is frequently associated with increased risk of toxicity, and (auto-) immune-related adverse events. The precise pathophysiologic mechanisms of these events are not yet clear, and evidence from clinical trials and translational studies remains limited. Our retrospective analysis of ~7700 metastatic melanoma patients treated with ipilimumab and/or nivolumab from the FDA Adverse Event Reporting System (FAERS) demonstrates that the identified immune-related reactions are specific to ipilimumab and/or nivolumab, and that when the two agents are administered together, their safety profile combines reactions from each drug alone. While more prospective studies are needed to characterize the safety of ipilimumab and nivolumab, the present work constitutes perhaps the first effort to examine the safety of these drugs and their combination based on computational evidence from real world post marketing data.

Diagnostics (Basel). 2018 Oct 31;8(4); Soldatos TG. doi: 10.3390/diagnostics8040076.

Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.